Marvel Medtech has developed a revolutionary way to defeat early-stage breast cancer by combining three unlikely counterparts: MRIs, cryotherapy, and the XJet Carmel 1400 Additive Manufacturing system.
Marvel Medtech is a US-based startup that is in business to battle breast cancer. Breast cancer kills more than 500,000 women worldwide each year. In the US alone, one in eight women will be diagnosed with breast cancer in their lifetime. Marvel Medtech’s innovation is a robotic guidance system that will destroy breast cancer cells at the time they are discovered – during breast magnetic resonance imaging (MRI) scans.
Ray Harter, President of Marvel Medtech, said, “Our new approach preempts the need for many biopsies, surgeries, radiation and chemotherapy treatments. Obviously, the expectation is that it’s likely to save many lives, but it will also dramatically improve the quality of life for patients. In addition, we also know that by eradicating those procedures, it will also reduce overall healthcare costs. And these are not insignificant savings – annually, these could be in the many billions of dollars.”
After identifying early-stage tumors during breast MRI scans, Marvel Medtech’s technology carefully targets the most dangerous cancer cells and applies cryoablation to freeze and destroy the cells before they could grow.
The technology transforms MRIs from a diagnostic-only tool into an actual treatment device.
The final challenge for Marvel Medtech was to develop the intricate probe that would work in conjunction with the MRI but not interfere with the machine’s magnetic field. The probe also needed to have very small features and possess complex geometry. 3D printing was the answer, but which printer could manufacture the appropriate material?
According to Harter:
“The tools used inside an MRI scanner must be compatible with strict safety guidelines, and crucially, not disrupt image quality. Because they are one of the most electrically insulating materials, ceramics are an ideal material to achieve this. However, we were unable to find a ceramic-based 3D printer able to accurately and cost effectively produce our ceramic probe. This is why we are adopting XJet’s Carmel 1400 solution.”
With XJet’s NanoParticle Jetting™ (NPJ) technology and the ability to 3D print zirconia (ceramic), Marvel Medtech was finally able to complete the last piece of their life-saving puzzle. They 3D printed the highly complex, ceramic cryotherapy probe. Now the company and its invention are poised to save thousands of lives, dramatically improve patient care, and save potentially billions of dollars in healthcare spending.
There are untold applications for 3D printing ceramic. Register for AMS 2020 and hear XJet’s Chief Business Officer, Dror Danai, talk about Marvel Medtech’s lifesaving probe at AMS 2020 in Boston, February 12 at 3:20. You will also hear him talk about other potential solutions NPJ technology can provide to industries around the world.
You May Also Like
Daimler Buses Relies on DyeMansion for Color & Texture Quality in 3D Printed Spare Parts
While it took decades for the rest of the world to catch up, a handful of aerospace organizations, automotive industry leaders, and other innovators have continued to enjoy the inside...
DyeMansion Completes Beta Testing of VaporFuse Surfacing Technology for 3D Printed Parts
3D printing offers a world of infinite potential for innovation, as well as combinations of materials and finishing processes. DyeMansion is just adding to all that goodness now with VaporFuse...
Why Automated Post Processing Makes Manufacturing With 3D Printers Possible
In Material Extrusion (FDM), we can now use inexpensive machines to make dimensionally accurate & tough parts in various materials at low cost. These parts can fulfill many industrial and...
3D Printing News Briefs: May 26, 2019
This year’s RAPID + TCT ended late last week at the Cobo Center in Detroit, so we’re again starting off today’s 3D Printing News Briefs with more news from the...
View our broad assortment of in house and third party products.